Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Does an enlarged spleen change the outlook for low platelet patients?

NCT ID NCT07182760

Knowledge-focused Sponsor: Assiut University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study will look at 100 adults with low platelet counts to see how many have an enlarged spleen and whether that affects their symptoms, complications, or response to treatment. The goal is to better understand the role of the spleen in these blood disorders. No new treatments are being tested.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2025

An estimate. Start dates often move.

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with isolated thrombocytopenia between 18 years to 65years

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * patients more than 18 years admitted with isolated thrombocytopenia due to primary Immune thrombocytopenic purpura amegakaryocytic aplasia Unilineage myelodysplastic syndrome ( megakaryocyte dysplasia) lymphoproliferative disorder with secondary ITP autoimmune diseases with secondary ITP Willingness to participate in the study Admitted patients or those who follow at hematology outpatients clinic Exclusion Criteria: EDTA induced pseudothrombocytopenia Platelet satellitism Drug induced thrombocytopenia Heparin induced thrombocytopenia / thrombosis syndrome post transfusion purpura Disseminated intravascular coagulopathy patients less than 18 years old patients with bicytopenia or pancytopenia Pregnancy \-

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Amegakaryocytic aplasia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

autoimmune thrombocytopenic purpura congenital amegakaryocytic thrombocytopenia lymphoproliferative syndrome myelodysplastic syndrome with single lineage dysplasia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Amegakaryocytic aplasia Autoimmune diseases with secondary ITP Lymphoproliferative disorder with secondary ITP Primary immune thrombocytopenic purpura Unilineage myelodysplastic syndrome ( megakaryocyte dysplasia)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.